Aisha Umbreen
Family Practice · Morgan Hill
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 6
- 2 carriers
- Offices
- 3
Offices
3 locations · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
6 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Aisha Umbreen’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
6 of 6 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A138688 · Current
Licensed to practise in California · since 2015 · expires 2027-10-31 · King Edward Medical University, Lahore.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Medicaid work
$1,152,702 in 2024
Medicaid paid $1,152,702 for 16,626 billed services this clinician did in 2024, up to 374 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 1,769 | $1,122,555 |
| Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 35 | $20,171 |
| Short return visit (20+ min) | 2,629 | $5,298 |
| Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use | 66 | $1,503 |
| Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use | 22 | $905 |
| Short return visit | 524 | $715 |
| New patient visit (30+ min) | 58 | $490 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose | 12 | $300 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 42 | $281 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 368 | $197 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 71 | $138 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 33 | $70 |
| 2024 | 16,626 | 31 | 374 | $1,152,702 |
| 2023 | 13,836 | 20 | 444 | $1,785,978 |
| 2022 | 6,182 | 10 | 183 | $875,900 |
| 2021 | 4,665 | 15 | 144 | $725,518 |
| 2020 | 3,665 | 7 | 158 | $316,839 |
| 2019 | 5,116 | 25 | 282 | $483,947 |
| 2018 | 4,348 | 10 | 247 | $606,637 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 2,834 | $1,742,361 |
| Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 39 | $22,476 |
| Short return visit (20+ min) | 4,446 | $15,133 |
| New patient visit (30+ min) | 193 | $1,835 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 312 | $1,536 |
| Short return visit | 385 | $1,035 |
| Return visit (30+ min) | 111 | $707 |
| Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use | 42 | $370 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 70 | $196 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 276 | $122 |
| URINE PREGNANCY TEST | 204 | $104 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 12 | $97 |
2022
| Clinic visit/encounter, all-inclusive | 1,454 | $867,544 |
| Short return visit (20+ min) | 2,705 | $8,251 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 76 | $80 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 92 | $25 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 215 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 613 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 94 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 112 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 694 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 127 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 1,405 | $716,326 |
| Short return visit (20+ min) | 2,181 | $3,895 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose | 43 | $1,720 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose | 32 | $1,280 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose | 31 | $1,240 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose | 12 | $480 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 12 | $480 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 55 | $78 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 48 | $19 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 118 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 257 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 55 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 1,343 | $312,805 |
| Short return visit (20+ min) | 1,534 | $2,178 |
| Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only | 225 | $1,459 |
| Short return visit | 319 | $308 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 38 | $50 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 69 | $39 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion | 137 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 1,869 | $467,199 |
| Short return visit (20+ min) | 1,573 | $5,633 |
| Thyroid stimulating hormone (TSH) | 91 | $1,733 |
| Hemoglobin A1C level | 150 | $1,650 |
| Blood test, lipids (cholesterol and triglycerides) | 95 | $1,442 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 131 | $810 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 91 | $803 |
| HEPATITIS C ANTIBODY | 45 | $728 |
| ELECTROLYTE PANEL | 84 | $668 |
| Basic metabolic panel (Calcium, total) This panel must include the following: Calcium, total (82310) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Potassium (84132) Sodium (84295) Urea nitrogen (BUN) (84520) | 50 | $479 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 12 | $477 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 12 | $463 |
2018
| Clinic visit/encounter, all-inclusive | 2,429 | $596,379 |
| Short return visit (20+ min) | 1,208 | $5,097 |
| New patient visit (30+ min) | 82 | $1,748 |
| Return visit (30+ min) | 290 | $1,648 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 182 | $1,415 |
| Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 17 | $160 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 45 | $152 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 68 | $34 |
| Blood glucose (sugar) level | 13 | $4 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 14 | $2 |
Drugs they prescribed that Part D paid
$47,940
Pharmacies billed $47,940 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (30 of 1,078) in 2024. Above the middle of the specialty; the typical family practice clinician is at 2%.
959 generic and fewer than 11 brand-name prescriptions · $47,940 in drug cost · 40 antibiotic prescriptions to 30 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Fluticasone Propionate Hfa | 11 | $3,834 | $349 |
| Albuterol Sulfate Hfa | 35 | $1,216 | $35 |
| Gabapentin | 34 | $779 | $23 |
| Repaglinide | 14 | $581 | $42 |
| Atorvastatin | 93 | $519 | $6 |
See all 23 drugs
| Fluticasone Propionate Hfa | 11 | $3,834 | $349 |
| Albuterol Sulfate Hfa | 35 | $1,216 | $35 |
| Gabapentin | 34 | $779 | $23 |
| Repaglinide | 14 | $581 | $42 |
| Atorvastatin | 93 | $519 | $6 |
| Oxycodone-Acetaminophen | 12 | $462 | $39 |
| Baclofen | 58 | $400 | $7 |
| Glipizide | 12 | $400 | $33 |
| Fluticasone Propionate | 39 | $350 | $9 |
| Levothyroxine | 29 | $321 | $11 |
| Losartan | 47 | $289 | $6 |
| Amlodipine Besylate | 75 | $289 | $4 |
| Lisinopril | 43 | $196 | $5 |
| Metformin | 36 | $178 | $5 |
| Montelukast | 17 | $165 | $10 |
| Simvastatin | 29 | $139 | $5 |
| Omeprazole | 22 | $131 | $6 |
| Diclofenac | 11 | $115 | $10 |
| Furosemide | 24 | $112 | $5 |
| Famotidine | 12 | $95 | $8 |
| Amoxicillin-Clavulanate Potass | 12 | $75 | $6 |
| Hydrochlorothiazide | 18 | $54 | $3 |
| Ibuprofen | 15 | $44 | $3 |
Year by year
| 2024 | 1,078 | 182 | 3% (30) | None | $47,940 |
| 2023 | 841 | 136 | 3% (23) | None | $68,415 |
| 2022 | 899 | 198 | 3% (24) | None | $72,547 |
| 2021 | 852 | 118 | 2% (14) | None | $74,864 |
| 2020 | 914 | 112 | 2% (18) | 20% | $102,844 |
| 2019 | 968 | 119 | 2% (17) | 21% | $74,840 |
| 2018 | 597 | 92 | 3% (15) | None | $33,674 |
| 2017 | 511 | 82 | None | None | $19,644 |
| 2016 | 429 | 43 | None | None | $24,467 |
| 2015 | 18 | None | None | None | $176 |
| 2014 | 17 | None | 0% (0) | None | $301 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Buprenorphine-Naloxone | 15 | $6,285 | $419 |
| Repaglinide | 15 | $4,859 | $324 |
| Symbicort | 11 | $4,858 | $442 |
| Suboxone | 11 | $2,909 | $264 |
| Gabapentin | 36 | $1,247 | $35 |
| Albuterol Sulfate Hfa | 22 | $887 | $40 |
| Amlodipine Besylate | 51 | $822 | $16 |
| Atorvastatin | 40 | $646 | $16 |
| Levothyroxine | 32 | $603 | $19 |
| Simvastatin | 36 | $575 | $16 |
| Losartan | 36 | $547 | $15 |
| Baclofen | 25 | $389 | $16 |
| Furosemide | 30 | $363 | $12 |
| Montelukast | 15 | $335 | $22 |
| Metformin | 30 | $289 | $10 |
| Lisinopril | 14 | $278 | $20 |
| Fluticasone Propionate | 30 | $276 | $9 |
| Famotidine | 11 | $188 | $17 |
| Omeprazole | 13 | $162 | $12 |
| Sertraline | 12 | $123 | $10 |
| Cyclobenzaprine | 15 | $101 | $7 |
| Triamcinolone Acetonide | 11 | $98 | $9 |
| Ibuprofen | 14 | $65 | $5 |
| Hydrochlorothiazide | 14 | $25 | $2 |
2022: 17 drugs
| Buprenorphine-Naloxone | 14 | $6,926 | $495 |
| Levothyroxine | 55 | $1,198 | $22 |
| Gabapentin | 33 | $1,108 | $34 |
| Amlodipine Besylate | 54 | $753 | $14 |
| Losartan | 32 | $539 | $17 |
| Atorvastatin | 44 | $479 | $11 |
| Simvastatin | 22 | $441 | $20 |
| Baclofen | 24 | $398 | $17 |
| Metformin | 42 | $339 | $8 |
| Fluticasone Propionate | 22 | $213 | $10 |
| Omeprazole | 15 | $198 | $13 |
| Furosemide | 29 | $189 | $7 |
| Triamcinolone Acetonide | 13 | $182 | $14 |
| Lisinopril | 14 | $144 | $10 |
| Cyclobenzaprine | 14 | $128 | $9 |
| Ibuprofen | 16 | $77 | $5 |
| Hydrochlorothiazide | 17 | $59 | $3 |
2021: 21 drugs
| Suboxone | 17 | $8,826 | $519 |
| Spiriva | 14 | $7,266 | $519 |
| Gabapentin | 38 | $1,080 | $28 |
| Levothyroxine | 43 | $882 | $21 |
| Ventolin Hfa | 14 | $738 | $53 |
| Albuterol Sulfate Hfa | 14 | $577 | $41 |
| Losartan | 30 | $483 | $16 |
| Atorvastatin | 47 | $442 | $9 |
| Simvastatin | 22 | $394 | $18 |
| Amlodipine Besylate | 30 | $392 | $13 |
| Metformin | 56 | $358 | $6 |
| Fluticasone Propionate | 28 | $299 | $11 |
| Bupropion Hcl Sr | 13 | $201 | $15 |
| Baclofen | 16 | $149 | $9 |
| Furosemide | 21 | $148 | $7 |
| Omeprazole | 18 | $130 | $7 |
| Niacin Er | 12 | $127 | $11 |
| Cyclobenzaprine | 16 | $108 | $7 |
| Lisinopril | 11 | $69 | $6 |
| Hydrochlorothiazide | 21 | $64 | $3 |
| Glipizide | 11 | $58 | $5 |
2020: 28 drugs
| Suboxone | 20 | $14,004 | $700 |
| Spiriva | 12 | $5,744 | $479 |
| Symbicort | 11 | $4,116 | $374 |
| Levothyroxine | 49 | $1,026 | $21 |
| Ventolin Hfa | 16 | $925 | $58 |
| Gabapentin | 51 | $829 | $16 |
| Atorvastatin | 58 | $630 | $11 |
| Losartan | 33 | $435 | $13 |
| Diclofenac | 13 | $318 | $24 |
| Bupropion Hcl Sr | 22 | $300 | $14 |
| Metoprolol | 14 | $258 | $18 |
| Metformin | 38 | $240 | $6 |
| Fluticasone Propionate | 26 | $235 | $9 |
| Niacin Er | 11 | $200 | $18 |
| Amlodipine Besylate | 34 | $198 | $6 |
| Pravastatin | 11 | $183 | $17 |
| Furosemide | 21 | $117 | $6 |
| Trazodone | 11 | $104 | $9 |
| Lisinopril | 21 | $103 | $5 |
| Simvastatin | 17 | $101 | $6 |
| Montelukast | 13 | $94 | $7 |
| Topiramate | 12 | $89 | $7 |
| Omeprazole | 14 | $82 | $6 |
| Hydrochlorothiazide | 20 | $76 | $4 |
| Cyclobenzaprine | 11 | $68 | $6 |
| Atenolol | 11 | $60 | $5 |
| Glipizide | 12 | $52 | $4 |
| Cephalexin | 11 | $48 | $4 |
2019: 31 drugs
| Suboxone | 21 | $14,418 | $687 |
| Symbicort | 12 | $7,289 | $607 |
| Ventolin Hfa | 24 | $1,369 | $57 |
| Levothyroxine | 45 | $1,275 | $28 |
| Gabapentin | 39 | $735 | $19 |
| Atorvastatin | 44 | $564 | $13 |
| Voltaren | 19 | $544 | $29 |
| Diclofenac | 16 | $434 | $27 |
| Metoprolol | 18 | $314 | $17 |
| Amlodipine Besylate | 51 | $263 | $5 |
| Metformin | 40 | $259 | $6 |
| Fluticasone Propionate | 19 | $235 | $12 |
| Losartan | 28 | $232 | $8 |
| Triamcinolone Acetonide | 11 | $217 | $20 |
| Niacin Er | 11 | $200 | $18 |
| Potassium Chloride | 11 | $174 | $16 |
| Tamsulosin | 11 | $165 | $15 |
| Nyamyc | 11 | $146 | $13 |
| Benazepril | 17 | $139 | $8 |
| Furosemide | 27 | $134 | $5 |
| Hydrochlorothiazide | 30 | $129 | $4 |
| Amoxicillin-Clavulanate Potass | 12 | $120 | $10 |
| Omeprazole | 20 | $116 | $6 |
| Pantoprazole | 13 | $115 | $9 |
| Baclofen | 12 | $108 | $9 |
| Montelukast | 14 | $106 | $8 |
| Trazodone | 11 | $89 | $8 |
| Simvastatin | 14 | $71 | $5 |
| Alendronate | 12 | $67 | $6 |
| Hydrocortisone | 12 | $60 | $5 |
| Cyclobenzaprine | 11 | $34 | $3 |
2018: 14 drugs
| Januvia | 11 | $5,390 | $490 |
| Levothyroxine | 30 | $656 | $22 |
| Atorvastatin | 38 | $444 | $12 |
| Oxybutynin Chloride | 16 | $334 | $21 |
| Metformin | 29 | $201 | $7 |
| Tamsulosin | 16 | $184 | $12 |
| Triamterene-Hydrochlorothiazid | 14 | $168 | $12 |
| Gabapentin | 15 | $167 | $11 |
| Amlodipine Besylate | 28 | $160 | $6 |
| Fluticasone Propionate | 19 | $153 | $8 |
| Losartan | 18 | $133 | $7 |
| Omeprazole | 15 | $76 | $5 |
| Montelukast | 13 | $70 | $5 |
| Ibuprofen | 18 | $60 | $3 |
2017: 17 drugs
| Ventolin Hfa | 15 | $779 | $52 |
| Celecoxib | 12 | $459 | $38 |
| Atorvastatin | 40 | $331 | $8 |
| Gabapentin | 29 | $263 | $9 |
| Levothyroxine | 13 | $234 | $18 |
| Amlodipine Besylate | 52 | $191 | $4 |
| Losartan | 19 | $148 | $8 |
| Metformin | 19 | $146 | $8 |
| Triamterene-Hydrochlorothiazid | 16 | $125 | $8 |
| Amoxicillin-Clavulanate Potass | 11 | $113 | $10 |
| Omeprazole | 15 | $111 | $7 |
| Baclofen | 12 | $83 | $7 |
| Montelukast | 12 | $83 | $7 |
| Lisinopril | 13 | $81 | $6 |
| Glipizide | 12 | $63 | $5 |
| Atenolol | 17 | $62 | $4 |
| Ibuprofen | 12 | $46 | $4 |
2016: 11 drugs
| Atorvastatin | 28 | $223 | $8 |
| Levothyroxine | 12 | $192 | $16 |
| Fluticasone Propionate | 14 | $155 | $11 |
| Omeprazole | 15 | $112 | $7 |
| Metoprolol | 11 | $105 | $10 |
| Furosemide | 21 | $80 | $4 |
| Metoprolol | 11 | $72 | $7 |
| Pantoprazole | 12 | $63 | $5 |
| Amlodipine Besylate | 16 | $56 | $3 |
| Hydrochlorothiazide | 13 | $42 | $3 |
| Citalopram Hbr | 12 | $35 | $3 |
Professional record
- NPI
- 1255764361
- Licence
- CA A138688California A138688: Current · expires 2027-10-31
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 751 S Bascom Ave, San Jose, CA, 95128
- NPI first listed
- 2013-08-12
- NPI last updated
- 2023-05-24
- NPI record certified
- 2023-05-24
This is when the NPI record was last certified, not a medical board exam.